4 recruiting, 3 not yet recruiting, 1 active not recruiting, 1 withdrawn. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 3, Not yet recruiting 2, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow Toripalimab-tpzi: new trials by email Literature Review of Toripalimab-tpzi trials Research Report on Toripalimab-tpzi
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Vanderbilt-Ingram Cancer Center | 20 | 2026-12-31 | 2026-09-23 |
| TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma TMV Vaccine, Toripalimab-tpzi - Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN) | Phase 1 | Recruiting | Metaclipse Therapeutics Corporation | 30 | 2026-10-01 | 2026-10-27 |
| Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status Toripalimab, Paclitaxel - Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | Phase 2 | Not yet recruiting | Barbara Ann Karmanos Cancer Institute | 22 | 2026-09-30 | 2026-08-31 |
| A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients NY-ESO-1 Peptide vaccine, Toripalimab-tpzi - Ovarian Cancer Stage IV, Ovarian Cancer Stage III | Phase 2 | Withdrawn | Georgetown University | 2026-09-01 | 2026-10-09 | |
| PDT For Induction Therapy For Head And Neck Cancer Toripalimab-tpzi, Cisplatin, Docetaxel - Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Recruiting | Massachusetts General Hospital | 26 | 2026-03-09 | 2026-10-19 |
| Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer Biopsy Procedure, Biospecimen Collection, Colonoscopy - Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 | Phase 2 | Recruiting | Emory University | 40 | 2025-09-19 | 2026-10-02 |
| Toripalimab With Chemotherapy for Sinus Cancer Toripalimab, Carboplatin, Docetaxel - Sinonasal Cancer, Paranasal Sinus Neoplasms | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 20 | 2025-06-17 | 2026-08-31 |
| A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors CHS-1000, Toripalimab - Advanced or Metastatic Solid Tumors | Phase 1 | Not yet recruiting | Coherus Oncology, Inc. | 48 | 2025-02-15 | 2024-09-19 |
| Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy Atezolizumab, Avelumab, Cemiplimab - Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm | Phase 1 | Active not recruiting | University of Southern California | 10 | 2020-08-12 | 2026-09-21 |
Head and Neck Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Squamous Cell (2) · Colonic Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Mouth Neoplasms (1) · Neoplasm Recurrence, Local (1) · Neoplasms (1) · Oropharyngeal Neoplasms (1) · Ovarian Neoplasms (1) · Paranasal Sinus Neoplasms (1) · Sinonasal undifferentiated carcinoma (1) · Skin Neoplasms (1)
Barbara Ann Karmanos Cancer Institute (1) · Coherus Oncology, Inc. (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · Georgetown University (1) · Massachusetts General Hospital (1) · Metaclipse Therapeutics Corporation (1) · University of Southern California (1) · Vanderbilt-Ingram Cancer Center (1)
United States (7)
Ammar Sukari, M.D. (1) · Christopher Pack, PhD (1) · Gino K In, MD (1) · Kartik Sehgal, MD (1) · Kristen Jacobsen, PhD (1) · Michael Coleman, PhD (1) · Michael Gibson (1) · Oluwadunni E. Emiloju, MBBS, MS (1) · Periasamy Selvaraj, PhD (1) · Samir N Khleif, MD (1) · Thomas Roberts, MD, MBA (1)
P30CA014089 (1), P30CA138292 (1)